Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin

10.1038/s41598-017-10325-x

Saved in:

Bibliographic Details
Main Authors:	Garg, M, Kanojia, D, Mayakonda, A, Ganesan, T.S, Sadhanandhan, B, Suresh, S, Sneha, S, Nagare, R.P, Said, J.W, Doan, N.B, Ding, L.-W, Baloglu, E, Shacham, S, Kauffman, M, Koeffler, H.P
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Article
Published:	Nature Publishing Group 2020
Subjects:	antineoplastic agent cell receptor doxorubicin exportin 1 protein hydrazine derivative karyopherin KPT-330 triazole derivative animal antagonists and inhibitors apoptosis biological model cancer transplantation cell cycle checkpoint disease model human thyroid carcinoma thyroid tumor treatment outcome tumor cell culture xenograft Animals Antineoplastic Agents Apoptosis Cell Cycle Checkpoints Disease Models, Animal Doxorubicin Heterografts Humans Hydrazines Karyopherins Models, Biological Neoplasm Transplantation Receptors, Cytoplasmic and Nuclear Thyroid Carcinoma, Anaplastic Thyroid Neoplasms Treatment Outcome Triazoles Tumor Cells, Cultured
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/174403
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-174403
record_format	dspace
spelling	sg-nus-scholar.10635-1744032024-04-24T05:48:36Z Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin Garg, M Kanojia, D Mayakonda, A Ganesan, T.S Sadhanandhan, B Suresh, S Sneha, S Nagare, R.P Said, J.W Doan, N.B Ding, L.-W Baloglu, E Shacham, S Kauffman, M Koeffler, H.P CANCER SCIENCE INSTITUTE OF SINGAPORE MEDICINE antineoplastic agent cell receptor doxorubicin exportin 1 protein hydrazine derivative karyopherin KPT-330 triazole derivative animal antagonists and inhibitors apoptosis biological model cancer transplantation cell cycle checkpoint disease model human thyroid carcinoma thyroid tumor treatment outcome tumor cell culture xenograft Animals Antineoplastic Agents Apoptosis Cell Cycle Checkpoints Disease Models, Animal Doxorubicin Heterografts Humans Hydrazines Karyopherins Models, Biological Neoplasm Transplantation Receptors, Cytoplasmic and Nuclear Thyroid Carcinoma, Anaplastic Thyroid Neoplasms Treatment Outcome Triazoles Tumor Cells, Cultured 10.1038/s41598-017-10325-x Scientific Reports 7 1 9749 2020-09-04T03:35:04Z 2020-09-04T03:35:04Z 2017 Article Garg, M, Kanojia, D, Mayakonda, A, Ganesan, T.S, Sadhanandhan, B, Suresh, S, Sneha, S, Nagare, R.P, Said, J.W, Doan, N.B, Ding, L.-W, Baloglu, E, Shacham, S, Kauffman, M, Koeffler, H.P (2017). Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Scientific Reports 7 (1) : 9749. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-017-10325-x 2045-2322 https://scholarbank.nus.edu.sg/handle/10635/174403 Nature Publishing Group Unpaywall 20200831
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	antineoplastic agent cell receptor doxorubicin exportin 1 protein hydrazine derivative karyopherin KPT-330 triazole derivative animal antagonists and inhibitors apoptosis biological model cancer transplantation cell cycle checkpoint disease model human thyroid carcinoma thyroid tumor treatment outcome tumor cell culture xenograft Animals Antineoplastic Agents Apoptosis Cell Cycle Checkpoints Disease Models, Animal Doxorubicin Heterografts Humans Hydrazines Karyopherins Models, Biological Neoplasm Transplantation Receptors, Cytoplasmic and Nuclear Thyroid Carcinoma, Anaplastic Thyroid Neoplasms Treatment Outcome Triazoles Tumor Cells, Cultured
spellingShingle	antineoplastic agent cell receptor doxorubicin exportin 1 protein hydrazine derivative karyopherin KPT-330 triazole derivative animal antagonists and inhibitors apoptosis biological model cancer transplantation cell cycle checkpoint disease model human thyroid carcinoma thyroid tumor treatment outcome tumor cell culture xenograft Animals Antineoplastic Agents Apoptosis Cell Cycle Checkpoints Disease Models, Animal Doxorubicin Heterografts Humans Hydrazines Karyopherins Models, Biological Neoplasm Transplantation Receptors, Cytoplasmic and Nuclear Thyroid Carcinoma, Anaplastic Thyroid Neoplasms Treatment Outcome Triazoles Tumor Cells, Cultured Garg, M Kanojia, D Mayakonda, A Ganesan, T.S Sadhanandhan, B Suresh, S Sneha, S Nagare, R.P Said, J.W Doan, N.B Ding, L.-W Baloglu, E Shacham, S Kauffman, M Koeffler, H.P Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
description	10.1038/s41598-017-10325-x
author2	CANCER SCIENCE INSTITUTE OF SINGAPORE
author_facet	CANCER SCIENCE INSTITUTE OF SINGAPORE Garg, M Kanojia, D Mayakonda, A Ganesan, T.S Sadhanandhan, B Suresh, S Sneha, S Nagare, R.P Said, J.W Doan, N.B Ding, L.-W Baloglu, E Shacham, S Kauffman, M Koeffler, H.P
format	Article
author	Garg, M Kanojia, D Mayakonda, A Ganesan, T.S Sadhanandhan, B Suresh, S Sneha, S Nagare, R.P Said, J.W Doan, N.B Ding, L.-W Baloglu, E Shacham, S Kauffman, M Koeffler, H.P
author_sort	Garg, M
title	Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
title_short	Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
title_full	Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
title_fullStr	Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
title_full_unstemmed	Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
title_sort	selinexor (kpt-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
publisher	Nature Publishing Group
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/174403
_version_	1800914238461444096

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin

Similar Items